Approvals· August 31, 2026 · 18 min read
Stelara's Pediatric UC License Does Not Write Wezlana Pediatric IBD Substitution
By Ran Chen#Biosimilars#Interchangeability#Purple Book
Topic
Immunology
IL-23, IL-17, JAK, TNF inhibitors, biologic access, payer coverage, step therapy, and immunology drug comparison.
Deals· July 31, 2026 · 19 min read
argenx's $2.2B Forte Biosciences Deal: FB102 Anti-CD122 & Vyvgart Synergy
By Ran Chen#M&A#Immunology#Clinical Evidence
Deals· July 21, 2026 · 17 min read
AbbVie's $10.9B Apogee Acquisition: The Zumilokibart Immunology Bet
By Ran Chen#M&A#Immunology#Payer Coverage
Deals· July 20, 2026 · 17 min read
2026 biopharma M&A by the numbers: 33 deals and $134 billion already eclipse all of 2025
By Ran Chen#M&A#Oncology#Immunology
Pricing & Access· July 16, 2026 · 23 min read
Atopic dermatitis systemic access: Dupixent, JAK inhibitors, and biologics
Pricing & Access· July 14, 2026 · 18 min read
Generalized Myasthenia Gravis (gMG) Access and Dosing Landscape
By Ran Chen#Rare Disease#Payer Policy#HCPCS Coding
Pricing & Access· July 12, 2026 · 20 min read
Lupus and SLE Access: Benlysta, Saphnelo, Lupkynis, and Autoimmune CAR-T
By Ran Chen#Payer Coverage#Payer Criteria#CAR-T
Pricing & Access· July 11, 2026 · 16 min read
Sanofi Portfolio Dossier: Dupixent Growth, Lantus Cliff, and Altuviiio Pivot
By Ran Chen#Immunology#Orange Book#Purple Book
Evidence· July 10, 2026 · 17 min read
Calcineurin Inhibitor Adverse Events in FAERS: 275,000 Reports and Key Safety Signals
Pricing & Access· July 9, 2026 · 18 min read
AbbVie Portfolio Dossier: Skyrizi, Rinvoq, and 2030s Patent Cliffs
By Ran Chen#Immunology#Orange Book#Purple Book